← Leaderboards
Priscilla Y. Hsue
University Of California, San Francisco
$28,957,856
Attributed
$55,457,501
Total exposure
21
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $9.6M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$55,457,501 · 21
By mechanism
R01$43,326,407 · 12
U01$3,312,870 · 1
R33$2,880,523 · 1
K24$1,875,200 · 1
K12$1,779,350 · 1
R56$827,657 · 1
Top collaborators
- Ahmed A Tawakol15 shared
- Neil C Chi9 shared
- Matthew S Freiberg9 shared
- Laurence Huang8 shared
- Peter W Hunt6 shared
- Todd M Bull5 shared
- Sonia Castro Flores5 shared
- Timothy Jensen Henrich5 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Robert M Stroud$50,842,733
- Hyewon Phee$598,050
- Sophie Huddart$523,260
- Akiko Hata$14,386,243
- Jennifer E Ho$11,062,788
Others in their field
Top investigators on “Cardiovascular Diseases”
- Chanza Baytop · Westat, Inc.$271,217,917
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$145,558,149
- Judith S. Currier · University Of California Los Angeles$143,001,230
- David M Nathan · Massachusetts Institute Of Technology$141,671,512
- John M Lachin · George Washington University$139,991,329
- Judith S Hochman · New York University School Of Medicine$112,514,057
Research focus
Cardiovascular DiseasesCohortHiv InfectionsCollaborationsInflammationChronicRisk FactorsAntiretroviral TherapyCardiovascular SystemInflammatoryInflammatory MarkerPathogenesisImmune ActivationEventCardiovascular Disorder RiskAtherosclerosisGeneral PopulationResearch PersonnelFutureT-LymphocytePersonsPathway InteractionsFundingMediating
Grant awards (85)
REVERSE-Long COVID: A Multicenter Randomized, Placebo-Controlled Clinical Trial of Immunomodulation (with Baricitinib) for Long COVID Related ADRD$6,107,805
R01 · FY2025 · AG
In Vivo PET Imaging of HIV Infection$735,024
R01 · FY2025 · AI
Evaluation of Novel Clonal Hematopoiesis Of InDEterminate Potential, Mosaic Chromosomal Alterations and CardioVascular Disease in HIV Infection (ENCODE CVD in HIV)$732,435
R01 · FY2025 · HL · contact PI
Cell-Type Specific Mechanisms of HIV Cardiomyopathy$697,477
R01 · FY2025 · HL
Cholesterol and inflammation Lowering via BEmpedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)$557,915
R01 · FY2025 · HL · contact PI
Heart and Lung Outcomes Post-TB (HALO Post-TB)$388,131
R01 · FY2025 · HL · contact PI
Heart and Lung Outcomes Post-TB (HALO Post-TB)$212,175
R01 · FY2025 · HL · contact PI
Evaluation of Novel Clonal Hematopoiesis Of InDEterminate Potential, Mosaic Chromosomal Alterations and CardioVascular Disease in HIV Infection (ENCODE CVD in HIV)$175,455
R01 · FY2025 · HL · contact PI
REVERSE-Long COVID: A Multicenter Randomized, Placebo-Controlled Clinical Trial of Immunomodulation (with Baricitinib) for Long COVID Related ADRD$5,665,215
R01 · FY2024 · AG
In Vivo PET Imaging of HIV Infection$736,856
R01 · FY2024 · AI
Evaluation of Novel Clonal Hematopoiesis Of InDEterminate Potential, Mosaic Chromosomal Alterations and CardioVascular Disease in HIV Infection (ENCODE CVD in HIV)$721,691
R01 · FY2024 · HL · contact PI
Cell-Type Specific Mechanisms of HIV Cardiomyopathy$699,504
R01 · FY2024 · HL
Heart and Lung Outcomes Post-TB (HALO Post-TB)$625,859
R01 · FY2024 · HL · contact PI
Cholesterol and inflammation Lowering via BEmpedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)$596,450
R01 · FY2024 · HL · contact PI
Evaluation of Novel Clonal Hematopoiesis Of InDEterminate Potential, Mosaic Chromosomal Alterations and CardioVascular Disease in HIV Infection (ENCODE CVD in HIV)$159,485
R01 · FY2024 · HL · contact PI
Role of Hematopoietic System and Proteomics in HIV-Associated CardiovascularDisease$129,817
K24 · FY2024 · AI · contact PI
Role of Hematopoietic System and Proteomics in HIV-Associated Cardiovascular Disease$63,695
K24 · FY2024 · AI · contact PI
Impact of Treating Asymptomatic CMV Replication on Cardiovascular Risk in Treated HIV Infection$765,877
R01 · FY2023 · HL
Evaluation of Novel Clonal Hematopoiesis Of InDEterminate Potential, Mosaic Chromosomal Alterations and CardioVascular Disease in HIV Infection (ENCODE CVD in HIV)$741,038
R01 · FY2023 · HL · contact PI
Cell-Type Specific Mechanisms of HIV Cardiomyopathy$707,225
R01 · FY2023 · HL
Cholesterol and inflammation Lowering via BEmpedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)$651,143
R01 · FY2023 · HL · contact PI
Role of Hematopoietic System and Proteomics in HIV-Associated Cardiovascular Disease$193,512
K24 · FY2023 · AI · contact PI
Impact of Treating Asymptomatic CMV Replication on Cardiovascular Risk in Treated HIV Infection$93,412
R01 · FY2023 · HL
Impact of Treating Asymptomatic CMV Replication on Cardiovascular Risk in Treated HIV Infection$78,069
R01 · FY2023 · HL
In Vivo PET Imaging of HIV Infection$737,195
R01 · FY2022 · AI
Impact of Treating Asymptomatic CMV Replication on Cardiovascular Risk in Treated HIV Infection$726,136
R01 · FY2022 · HL
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)$721,297
R33 · FY2022 · HL · contact PI
Cell-Type Specific Mechanisms of HIV Cardiomyopathy$712,801
R01 · FY2022 · HL
Cholesterol and inflammation Lowering via BEmpedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)$698,084
R01 · FY2022 · HL · contact PI
UCSF Career Development Program in Cardiopulmonary, Hematologic, and Immunologic Comorbidities of HIV (CHIC)$419,849
K12 · FY2022 · HL
Role of Hematopoietic System and Proteomics in HIV-Associated Cardiovascular Disease$193,512
K24 · FY2022 · AI · contact PI
In Vivo PET Imaging of HIV Infection$738,002
R01 · FY2021 · AI
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)$721,297
R33 · FY2021 · HL · contact PI
Impact of Treating Asymptomatic CMV Replication on Cardiovascular Risk in Treated HIV Infection$668,476
R01 · FY2021 · HL
UCSF Career Development Program in Cardiopulmonary, Hematologic, and Immunologic Comorbidities of HIV (CHIC)$419,849
K12 · FY2021 · HL
Role of Hematopoietic System and Proteomics in HIV-Associated Cardiovascular Disease$193,512
K24 · FY2021 · AI · contact PI
In Vivo PET Imaging of HIV Infection$731,949
R01 · FY2020 · AI
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)$721,297
R33 · FY2020 · HL · contact PI
Impact of Treating Asymptomatic CMV Replication on Cardiovascular Risk in Treated HIV Infection$675,844
R01 · FY2020 · HL
UCSF Career Development Program in Cardiopulmonary, Hematologic, and Immunologic Comorbidities of HIV (CHIC)$419,849
K12 · FY2020 · HL
Role of Hematopoietic System and Proteomics in HIV-Associated Cardiovascular Disease$193,512
K24 · FY2020 · AI · contact PI
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)$716,632
R33 · FY2019 · HL · contact PI
Protein Biomarkers for CVD Prediction in HIV-Infected and Uninfected Veterans$698,276
R01 · FY2019 · HL · contact PI
UCSF Career Development Program in Cardiopulmonary, Hematologic, and Immunologic Comorbidities of HIV (CHIC)$419,849
K12 · FY2019 · HL
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)$729,903
R61 · FY2018 · HL · contact PI
Protein Biomarkers for CVD Prediction in HIV-Infected and Uninfected Veterans$711,851
R01 · FY2018 · HL · contact PI
HIV Viral Reservoirs and Monocyte Activation in HIV-Associated Atherosclerosis$181,528
K24 · FY2018 · AI · contact PI
UCSF Career Development Program in Cardiopulmonary, Hematologic, and Immunologic Comorbidities of HIV (CHIC)$99,954
K12 · FY2018 · HL
Effect of IL-1B inhibition on inflammation and cardiovascular risk in HIV$1,274,950
R01 · FY2017 · HL · contact PI
Protein Biomarkers for CVD Prediction in HIV-Infected and Uninfected Veterans$699,392
R01 · FY2017 · HL · contact PI
Genotypic and functional properties of HIV-1 Nef clinical isolates in PAH-HIV$652,473
U01 · FY2017 · HL
HIV Viral Reservoirs and Monocyte Activation in HIV-Associated Atherosclerosis$181,528
K24 · FY2017 · AI · contact PI
Effect of IL-1B inhibition on inflammation and cardiovascular risk in HIV$1,194,567
R01 · FY2016 · HL · contact PI
Protein Biomarkers for CVD Prediction in HIV-Infected and Uninfected Veterans$756,117
R01 · FY2016 · HL · contact PI
Genotypic and functional properties of HIV-1 Nef clinical isolates in PAH-HIV$661,360
U01 · FY2016 · HL
Effect of low dose methotrexate on endothelial function and inflammation in HIV$305,126
R01 · FY2016 · HL · contact PI
HIV Viral Reservoirs and Monocyte Activation in HIV-Associated Atherosclerosis$181,528
K24 · FY2016 · AI · contact PI
Genotypic and functional properties of HIV-1 Nef clinical isolates in PAH-HIV$670,558
U01 · FY2015 · HL
HIV Viral Reservoirs and Monocyte Activation in HIV-Associated Atherosclerosis$181,528
K24 · FY2015 · AI · contact PI
Effect of IL-1B inhibition on inflammation and cardiovascular risk in HIV$51,766
R01 · FY2015 · HL · contact PI
Effect of IL-1B inhibition on inflammation and cardiovascular risk in HIV$827,657
R56 · FY2014 · HL · contact PI
Genotypic and functional properties of HIV-1 Nef clinical isolates in PAH-HIV$664,156
U01 · FY2014 · HL
Effect of low dose methotrexate on endothelial function and inflammation in HIV$634,295
R01 · FY2014 · HL · contact PI
HIV Viral Reservoirs and Monocyte Activation in HIV-Associated Atherosclerosis$181,528
K24 · FY2014 · AI · contact PI
Genotypic and functional properties of HIV-1 Nef clinical isolates in PAH-HIV$664,323
U01 · FY2013 · HL
Effect of low dose methotrexate on endothelial function and inflammation in HIV$617,919
R01 · FY2013 · HL · contact PI
Inflammation, Viral Replication, and Atherosclerosis in Treated HIV Infection$990,050
R01 · FY2012 · HL · contact PI
Effect of low dose methotrexate on endothelial function and inflammation in HIV$657,753
R01 · FY2012 · HL · contact PI
Inflammation, Viral Replication, and Atherosclerosis in Treated HIV Infection$1,000,114
R01 · FY2011 · HL · contact PI
Epidemiology and Pathogenesis of Pulmonary Hypertension in HIV Patients$540,833
R01 · FY2011 · HL · contact PI
Inflammation, Viral Replication, and Atherosclerosis in Treated HIV Infection$998,266
R01 · FY2010 · HL · contact PI
Epidemiology and Pathogenesis of Pulmonary Hypertension in HIV Patients$611,808
R01 · FY2010 · HL · contact PI
Inflammation, Viral Replication, and Atherosclerosis in Treated HIV Infection$114,728
R01 · FY2010 · HL · contact PI
Inflammation, Viral Replication, and Atherosclerosis in Treated HIV Infection$1,004,250
R01 · FY2009 · HL · contact PI
Epidemiology and Pathogenesis of Pulmonary Hypertension in HIV Patients$605,361
R01 · FY2009 · HL · contact PI
Pathogenesis of Atherosclerosis in HIV Patients on HAART$121,770
K23 · FY2009 · AI · contact PI
Inflammation, Viral Replication, and Atherosclerosis in Treated HIV Infection$1,004,250
R01 · FY2008 · HL · contact PI
Epidemiology and Pathogenesis of Pulmonary Hypertension in HIV Patients$646,880
R01 · FY2008 · HL · contact PI
Pathogenesis of Atherosclerosis in HIV Patients on HAART$121,770
K23 · FY2008 · AI · contact PI
Epidemiology and Pathogenesis of Pulmonary Hypertension in HIV Patients$671,127
R01 · FY2007 · HL · contact PI
Pathogenesis of Atherosclerosis in HIV Patients on HAART$121,770
K23 · FY2007 · AI · contact PI
Pathogenesis of Atherosclerosis in HIV Patients on HAART$121,770
K23 · FY2006 · AI · contact PI
Pathogenesis of Atherosclerosis in HIV Patients on HAART$121,770
K23 · FY2005 · AI
IMMUNOLOGIC AND INFLAMMATORY FACTORS IN PATIENTS WITH HIV$72,015
M01 · FY2005 · RR
HHV-8 AND PULMONARY ARTERIAL PRESSURES IN PATIENTS WITH HIV INFECTION$44,726
M01 · FY2005 · RR